Cancer Network spoke with Dr. Karyn Goodman about the importance of developing a systematic therapy regimen for the treatment of esophagogastric cancer.
Karyn A. Goodman, MD
Advertisement
Articles by Karyn A. Goodman, MD
ACR Appropriateness Criteria® Borderline and Unresectable Pancreas Cancer
ByWilliam Small, Jr, MD,John P. Hayes, MD,W. Warren Suh, MD, MPH,May Abdel-Wahab, MD, PhD,Ross A. Abrams, MD,Nilofer Azad, MD,Prajnan Das, MD, MS, MPH,Jadranka Dragovic, MD,Karyn A. Goodman, MD,Salma K. Jabbour, MD,William E. Jones III, MD,Andre A. Konski, MD, MBA, MA,Albert C. Koong, MD, PhD,Rachit Kumar, MD,Percy Lee, MD,Timothy M. Pawlik, MD,Joseph M. Herman, MD, MSc
These guidelines review the use of radiation, chemotherapy, and surgery in borderline and unresectable pancreas cancer. Radiation technique, dose, and targets were evaluated, as was the recommended chemotherapy, administered either alone or concurrently with radiation. This report will aid clinicians in determining guidelines for the optimal treatment of borderline and unresectable pancreatic cancer.
ACR Appropriateness Criteria® Resectable Stomach Cancer
ByParima Daroui, MD, PhD,Salma K. Jabbour, MD,Joseph M. Herman, MD, MSc,May Abdel-Wahab, MD, PhD,Nilofer Azad, MD,A. William Blackstock, MD,Prajnan Das, MD,Karyn A. Goodman, MD,Theodore S. Hong, MD,William E. Jones III, MD,Harmeet Kaur, MD,Andre A. Konski, MD, MBA, MA,Albert C. Koong, MD, PhD,Rachit Kumar, MD,Timothy M. Pawlik, MD,William Small, Jr, MD,Charles R. Thomas, Jr, MD,W. Warren Suh, MD, MPH
For resectable gastric cancer, perioperative chemotherapy or adjuvant chemoradiation with chemotherapy are standards of care. The decision making for adjuvant therapeutic management can depend on the stage of the cancer, lymph node positivity, and extent of surgical resection.
ACR Appropriateness Criteria® Rectal Cancer: Metastatic Disease at Presentation
ByKaryn A. Goodman, MD,Sarah A. Milgrom, MD,Joseph M. Herman, MD, MSc,May Abdel-Wahab, MD, PhD,Nilofer Azad, MD,A. William Blackstock, MD,Prajnan Das, MD,Theodore S. Hong, MD,Salma K. Jabbour, MD,William E. Jones III, MD,Andre A. Konski, MD, MBA, MA,Albert C. Koong, MD, PhD,Rachit Kumar, MD,Miguel Rodriguez-Bigas, MD,William Small, Jr, MD,Charles R. Thomas, Jr, MD,W. Warren Suh, MD
The management of rectal cancer in patients with metastatic disease at presentation is highly variable. Although chemoradiation is standard for patients with stage II/III rectal cancer, its role in the metastatic setting is controversial.
In this issue of ONCOLOGY, Drs. Patel, Puthillath, Yang, and Fakih discuss the evolution of adjuvant therapy for locally advanced rectal cancer from postoperative to preoperative radiation and provide a fairly comprehensive review of the data on adjuvant/neoadjuvant chemoradiation for rectal cancer. The authors then attempt to critically evaluate the use of combination chemotherapy regimens in the neoadjuvant setting, asking the question, “Is more better?”
Advertisement
Latest Updated Articles
- Making Rational Choices to Improve Neoadjuvant Chemoradiation for Rectal Cancer
Published: June 2nd 2008 | Updated:
- ACR Appropriateness Criteria® Rectal Cancer: Metastatic Disease at Presentation
Published: October 15th 2014 | Updated:
- ACR Appropriateness Criteria® Resectable Stomach Cancer
Published: August 15th 2015 | Updated:
- ACR Appropriateness Criteria® Borderline and Unresectable Pancreas Cancer
Published: July 15th 2016 | Updated:
Developing Systemic Therapy for Esophagogastric CancerPublished: February 8th 2019 | Updated:
Advertisement
Advertisement
